NCT02112214

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date: Jun 1, 2014
Primary completion: Dec 1, 2027
Completion date: Dec 1, 2027
First posted: —
Last posted: —
Enrollment: 11000
Arms / groups: 2 / —
Source: AACT · pre-existing

Sponsors

National Cancer Center, KoreaLead sponsor
International Agency for Research on CancerCollaborator
Catholic University of KoreaCollaborator
Chonnam National UniversityCollaborator
National Cancer Center, KoreaOverall official - principal investigator
International Agency for Research on CancerOverall official - principal investigator
Chonnam National UniversityOverall official - principal investigator
Catholic University of KoreaOverall official - principal investigator
National Cancer Center, KoreaReponsible party - principal investigator
Hallym UniversityCollaborator
Kyungpook UniversityOverall official - principal investigator
Kyungpook UniversityCollaborator
Seoul National UniversityCollaborator
Chung-Ang UniversityOverall official - principal investigator
Chung-Ang UniversityCollaborator
Pusan National UniversityOverall official - principal investigator
Pusan National UniversityCollaborator

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.